You are totally right, House. That was why one reason to run the murine study independently of Madrigal -- so we would own the data. If Madrigal funded the trial, they could publish whatever parts of the data they wanted to publish, and not make public the fact that Leron outperformed Resmetirom. Now we are free to turn to whatever partner wants a piece of the MASH action. Today's sp action does NOT reflect the corner we've turned here. It might be a mouse study, but it was the mouse study that roared.